This indicator shows trends in deaths from chronic liver diseases among people with chronic hepatitis B and C.
Definition:
Combined mortality rate from HCC, cirrhosis and chronic liver diseases attributable to chronic hepatitis B and C per 100,000 population
Disaggregation:
By country and WHO region
Method of measurement
This indicators involves estimating number of deaths from HCC, cirrhosis and chronic liver diseases attributable to hepatitis B and C. Given the strong association between hepatitis B and C and chronic liver disease, as a first approximation, the proportion of people with HCC, decompensated cirrhosis and chronic liver disease who have chronic hepatitis B or C is used to estimate the fraction of these sequelae that are attributable to hepatitis B and C.
Modelling using the PRoGReSs (for HBV) and Markov (disease progression) model for HCV. Estimates of HBV and HCV mortality are produced through a consultative and analytical process led by WHO. Estimates are then validated by countries ahead of publication in in WHO.
M&E Framework:
Impact
Method of estimation:
Numerator : Number of deaths attributed to hepatitis B plus Number of deaths attributed to hepatitis C(multiplied by 100,000)
Denominator: Total population of the specified reporting year
Method of estimation of global and regional aggregates:
Regional estimates are the sum of the country data in each WHO region.
Preferred data sources:
Number of deaths from hepatitis B and C retrieved from national vital registries and cancer registries
Global disease burden estimates from the Institute for Health Metrics and Evaluation (aggregated data)
IARC Cancer Incidence in Five Continents (CI5) databases (liver cancer and HCC data)
Global estimated data (modelling)
IARC GLOBOCAN database (liver cancer ICD-10 code C22 only)
If you have any feedback, you are welcome to write it here.
If you need to access the old Global Health Observatory data, you can do it here. But before you leave, please provide us your feedback about our new data portal.
